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Abstract 
Purpose: To investigate the effect of Dihuang Rougui Decoction (DRD) on ovariectomy-induced 
osteoporosis in rats.  
Methods: Female Sprague-Dawley rats were randomly assigned to a normal group (control) and five 
ovariectomy (OVX) subgroups: OVX with vehicle (OVX), OVX with positive control drug (alendronate 
sodium tablets, 1.6 mg/kg/week), and OVX + DRD (75, 150 or 300 mg/kg/day). After the rats were 
subjected to ovariectomy for 4 weeks, fosamax or DRD were administered daily (orally) for 16 weeks. 
The bone mineral density (BMD) of the L4 vertebrae and right femurs of the rats was evaluated. Serum 
hormones estradiol (E2), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels and 
serum alkaline phosphatase (ALP), osteocalcin (OC) and telopeptides of collagen type I (CTx) levels of 
the rats were determined. The bone tissue morphology of the rats was examined by microscopy.  
Results: The results show that DRD dose-dependently inhibited bone mineral density (BMD) reduction 
of L4 vertebrae and femurs (both p < 0.05). DRD significantly increased serum E2, FSH and LH levels 
(p < 0.05) in the osteoporotic rats, and significantly lowered serum ALP, CTx and OC concentrations, 
compared to OVX group (p < 0.01). Compared with OVX model group, bone trabeculae in all three DRD 
groups and nilestriol groups were wider, and the space and connections markedly increased. 
Furthermore, the medullary cavity reduced in size. 
Conclusion: These findings indicate that DRD mitigates OVX-induced osteoporosis in rats, and thus, 
the decoction has a potential for clinical management of osteoporosis patients. 
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Postmenopausal osteoporosis is a type of 
systemic bone disease characterized by a 
reduction in bone density, degradation of bone 
microstructure and an alteration in serum 
markers of bone metabolism, such as alkaline 
phosphatase (ALP), estradiol (E2) and 
interleukin-6 (IL-6) in postmenopausal females. 
This results in bone fragility and an increased 
risk of fracture. Approximately one third of 
postmenopausal females suffer from 
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osteoporosis and this is usually due to the 
marked reduction in estrogen levels [1].  
 
According to data released by World Health 
Organization (WHO), osteoporosis affects 
approximately million people throughout Europe, 
USA, and Japan [2]. Incidence of osteoporosis 
increases dramatically with life expectancy. 
Accordingly, the risk of osteoporotic fractures 
and their associated costs is rising rapidly due to 
aging population [3]. In the elderly, hip fractures 
are closely associated with mortality [4]. 
Hormone deficiency is known to impair 
cancellous metaphyseal and reduce BMD in 
humans and animals. Therefore, estrogen 
deficiency in post-menopausal women has been 
regarded as a critical cause of this population’s 
susceptibility to osteoporosis [5]. Osteoporosis is 
twice as common in women as in men [6], and 
approximately one in three women over 50 years 
old experiences an osteoporotic fracture in her 
life time [7]. 
 
Clinically, hormone replacement therapy (HRT) 
has been a popular therapeutic strategy 
designed for postmenopausal osteoporosis [8,9]. 
However, long-term application of HRT has 
potential malignant effects on reproductive 
tissues [10-12]. Other medicines that stimulate 
bone formation (e.g., growth hormone, sodium 
uoride, and parathyroid hormone) or inhibit bone 
resorption (e.g., bisphosphonates and calcitonin) 
may prevent bone loss progression in 
established osteoporosis. However, these drugs 
are not effective for a large proportion of the 
world population, especially in developing 
countries, and their drugs have side effects, such 
as gastrointestinal reactions, cancers, 
osteonecrosis of the jaw, and reduced skeletal 
strength [13,14]. Consequently, to substitute or 
reduce the medicines used currently, there are 
efforts to develop new drugs with improved 
therapeutic efficacy, fewer undesirable side 
effects, and lower cost. 
 
Dihuang Rougui Decoction is a traditional 
Chinese medicine composed of Codonopsis 
pilosula (Franch.) Nannf. 3 gram, 
Rehmannia glutinosa (Gaetn.) Libosch. ex Fisch. 
et Mey. 4 gram, Pinellia ternata (Thunb.) Breit. 2 
gram, Angelica sinensis (Oliv.) Diels 2 gram, 
Evodia rutaecarpa (Juss.) Benth. 7 gram and 
Cinnamomum cassia Presl 6 gram, which has 
been commonly used as an anti-aging agent, 
anti-osteoporosis and aphrodisiac in Chinese 
traditional medicine [15].  
 
This study was carried out to investigate the 
therapeutic effects of DRD on ovariectomy-
induced osteoporosis in rats. 
EXPERIMENTAL 
 
Preparation of Dihuang Rougui decoction 
 
The herbal samples of Dihuang Rougui 
Decoction were collected from Guilin City, 
Guangxi Province in China in November 2016. 
Taxonomic identification of the plant was 
performed by Professor Gang Hu of College of 
pharmacy, Liaoning University of Traditional 
Chinese Medicine, in Shenyang of China. A 
voucher specimen (no. DRD 201611023) was 
deposited in the herbarium of college of 
pharmacy, Liaoning University of Traditional 
Chinese Medicine, Shenyang, China for future 
reference. Dihuang Rougui Decoction was 
provided by the manufacturing laboratory of 
Orthopedic Hospital of Shenyang. 
 
Animals and treatments 
 
Healthy six-month-old female Sprague-Dawley 
rats (weighing 220 ± 20 g) were provided by 
Liaoning Province Experimental Animal center 
(certificate no. SYXK2002-0003). The animals 
had free access to feed and water, and were 
allowed to acclimatize for at least one week 
before use. The rat experiment was approved by 
Animal Care and Use Committee of Orthopedic 
Hospital of Shenyang (approval ref no. 
200607856) and was carried out in compliance 
with Directive 2010/63/EU on the handling of 
animals used for scientific purposes [16]. 
 
Sixty rats were randomly divided into six groups 
of ten a group (control) and five ovariectomy 
(OVX) subgroups, that is, OVX with vehicle 
(OVX), OVX with positive control drug, 
alendronate sodium tablets (ASD, 1.6 
mg/kg/week), and OVX with DRD doses 75, 150 
or 300 mg/kg/day. 
 
BMD measurement  
 
The BMD of the L1-5 vertebrae and right femurs 
was estimated using dual-energy X-ray 
absorptiometry scanning (DEXA, GE Healthcare, 
USA) with small animal measurement. The 
measurement was expressed as mineral grams 
per cm2 of surface area. Scans were performed 
by the same blinded technician. 
 
Serum E2, FSH and LH levels in rats treated 
with DRD 
 
After the rats were sacrificed by cervical 
dislocation,  serum was obtained by removing 
the eyeball. And serum E2, FSH and LH levels of 
rats were    determined by ELISA method 
(provided by Nanjing built Biological     
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Engineering Research Institute Co., Ltd. Nanjing, 
China). 
 
Serum bone marker in rats treated with DRD 
 
Rat serum alkaline phosphatase (ALP), 
osteocalcin (OC) and telopeptides of collagen 
type I (CTx) levels were determined by ELISA 
method (provided by Nanjing built Biological 





The data are expressed as mean ± SD. 
Statistical analysis was performed using one-way 
ANOVA combined with Bonferroni’s multiple 
comparison test using SPSS 16.0. Differences 





BMD of L1-5 vertebrae and femurs 
 
The BMD of L1-5 vertebrae and femurs is 
presented in Table 1. These results demonstrate 
that OVX significantly decreased BMD in the L4 
vertebrae and femurs compared to the control 
group (p < 0.05). Compared to the OVX group, 
DRD treatment significantly decreased the BMD 
in OVX-induced L4 vertebrae and femurs (all p < 
0.05) in a dose-dependent manner. The positive 
control drug Fosamax also significantly increased 
the BMD of the L4 vertebrae and femurs (both p 
< 0.05), which was similar to that observed in the 
H-DRD group (p > 0.05). 
 
Table 1: Effect of DRD on BMD of L4 vertebrae and 
femurs (n = 10) 
 




BMD of femur  
(g/cm2) 
Control - 0.92±0.04* 0.64±0.05* 
OVX - 0.25±0.05 0.16±0.04 
ASD 1.6 0.32±0.04* 0.34±0.03* 
L-DRD 75 0.30±0.04* 0.25±0.04* 
M-DRD 150 0.33±0.03* 0.23±0.04* 
H-DRD 300 0.72±0.04* 0.44±0.03* 
*P < 0.05 and **p < 0.01 versus OVX group. L-DRD = 
low dose of DRD, M-DRD = middle dose of DRD, H-
DRD = high dose of DRD, ASD: Alendronate Sodium 
Tablets  
 
Effect of DRD on serum E2, FSH and LH 
levels 
 
Compared to control group, serum E2, FSH and 
LH levels decreased significantly in OVX group 
rats (p < 0.01). Compared to the OVX group, 
DRD treatment significantly increased serum E2, 
FSH and LH levels (p < 0.05) in a dose-
dependent manner in rats (Table 2). 
 







(pmol/L) FSH (IU/L) 
LH 
(mIU/mL) 
Control - 8.57±0.18** 2.84±0.05** 3.43±0.12* 
OVX - 1.37±0.13 0.41±0.03 1.24±0.06 
ASD 1.6 4.26±0.15** 1.78±0.04* 2.26±0.04* 
L-DRD 75 2.46±0.22 0.92±0.04 1.82±0.11 
M-DRD 150 3.65±0.28* 1.51±0.05* 2.38±0.06* 
H-DRD 300 4.34±0.19** 1.80±0.03** 2.82±0.07* 
*p < 0.05 and **p < 0.01 versus OVX group. L-DRD: 
low dose of DRD, M-DRD: middle dose of DRD, H-
DRD: high dose of DRD, ASD: Alendronate Sodium 
Tablets  
 
Effect of DRD on serum ALP, CTx and OC 
concentrations  
 
Serum ALP, CTx, and OC concentrations in the 
OVX group were significantly higher as 
compared to the control group. After four weeks 
of treatment, the DRD 300 mg/kg-treated group 
showed significantly lower serum ALP, CTx and 
OC concentrations compared to the OVX group 
(p < 0.01) (Table 3).  
 
Table 3: Effect of DRD on serum ALP, CTx, and OC 









Control - 123.5±3.8 27.6±1.7 46.4±2.0 
OVX - 256.5±5.8** 82.1±1.5** 82.3±2.4** 
ASD 1.6 177.2±4.9** 53.3±2.4** 51.3±1.3** 
L-DRD 75 223.6±5.8 76.1±2.3 78.5±1.8 
M-DRD 150 176.5±4.3* 67.8±1.4* 73.2±1.3* 
H-DRD 300 152.4±3.9** 52.3±2.3** 60.5±1.4** 
*P < 0.05 and **p < 0.01 versus OVX group. L-DRD: 
low dose of DRD, M-DRD: middle dose of DRD, H-





Postmenopausal osteoporosis is a systematic 
imbalance in which the speed of bone resorption 
is greater than bone formation. This disease is 
caused by estrogen deficiency and results in 
micro-architectural changes, particularly bone 
remodeling. Certain critical molecules co-
ordinate the actions of osteoblasts and 
osteoclasts during bone remodeling. Therefore, 
the development of new preventive and 
therapeutic drugs for osteoporosis is urgently 
needed. In recent decades, Chinese medicinal 
herbal extracts have been extensively 
investigated for their pharmacological effects 
related to bone protection [17]. Decreased BMD 
Du et al 
426 
 
is one of the major factors that jeopardize bone 
strength, resulting in increased susceptibility to 
fractures. Thus, BMD measurement can best 
predict fracture risk [18]. The results in the 
present study showed that OVX reduced BMD in 
the right femurs and L4 vertebrae, which are rich 
in trabecular bone, while treatment with DRD 
dose-dependently prevented the decreases in 
BMD. Although BMD is among the strongest 
predictors of facture resistance, both empirical 
observations and theoretical analyses show that 
the biomechanical properties of bone and 
trabecular microarchitecture influence trabecular 
bone strength as well [19].  
 
Estradiol plays an important role in sclerotin of 
humans. When female serum estradiol level 
decreases significantly, osteoporosis will occur 
[20]. Compared to the OVX group, DRD 
treatment significantly increased serum E2, FSH 
and LH levels in a dose-dependent manner in 
rats. In our experiments, OVX resulted in 
significant decrease in femur BMD after four 
weeks. The BMD loss was accompanied by a 
significant increase in bone remodeling, as 
evidenced by the increased biochemical bone 
turnover markers, such as serum ALP, CTx, and 
OC levels [21]. In the present study, oral 
administration of DRD at the dose 248 mg/kg 
significantly decreased BMD loss, which was 
accompanied by the decrease in serum ALP, 
CTx, and OC levels compared to a OVX control 
group. These results suggest that Bushen Jiangu 
Decoction could decreases bone loss by 




The findings of this work indicate that DRD 
prevents OVX-induced osteoporosis in rats, and 
therefore can potentially be used for the 
treatment of postmenopausal osteoporosis of 
elderly women in future. However, further studies 
on the toxicity and safety of the decoction, as 
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